

According to Regulation (EC) No 1907/2006

According to Regulation (EC) No 2020/878

Doxorubicin hydrochloride

Version number: 2
Issued: 2024-02-01
Replaces SDS: 2019-03-27



SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Trade name

Doxorubicin hydrochloride

CAS number

25316-40-9

EC number

246-818-3

Synonyms

(8S-cis)-10-[(3-amino-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-tri-hydroxy-8-(hydroxyacetyl)-1-methoxynaphthacene-5,12-dione hydrochloride

1.2. Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses

Research and development. Laboratory Chemicals. Manufacture of substances.

Not suitable for use in

Not suitable for human consumption or veterinary purposes.

1.3. Details of the supplier of the safety data sheet

Supplier

Molekula Group

Address

Molekula Ltd, Lingfield Way, Darlington,
DL1 4XX Darlington
United Kingdom

Telephone

+44 (0) 3302 000 333

Email

info@molekula.com

Web site

www.molekula.com

Contact person

Kevin Banks

Email

+44 (0) 7769276927

According to Regulation (EC) No 1907/2006

According to Regulation (EC) No 2020/878

Doxorubicin hydrochloride

Version number: 2
 Issued: 2024-02-01
 Replaces SDS: 2019-03-27



1.4. Emergency telephone number

Poison center/Additional emergency number

0344 892 0111 - National Poisons Information Service (Newcastle Centre)

SECTION 2: Hazards identification

2.1. Classification of the substance or mixture

Classification according to Regulation (EC) No 1272/2008

Classification

Carcinogenicity, hazard category 1B

Acute toxicity, oral, hazard category 4

Hazard statements

H302, H350

2.2. Label elements

Labelling according to Regulation (EC) No 1272/2008

Hazard pictograms



Signal word

Danger

Hazard statements

H302 Harmful if swallowed.

H350 May cause cancer.

Precautionary statements

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read and understood.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P280 Wear protective gloves/protective clothing/eye protection/face protection.

P330 Rinse mouth.

P301 + P312 IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell.

P308 + P313 IF exposed or concerned: Get medical advice/attention.

P405 Store locked up.

P501 Dispose of contents/container to local regulations.

2.3. Other hazards

No data available

According to Regulation (EC) No 1907/2006

According to Regulation (EC) No 2020/878

Doxorubicin hydrochloride

Version number: 2
 Issued: 2024-02-01
 Replaces SDS: 2019-03-27



SECTION 3: Composition/information on ingredients

3.2. Mixtures

Chemical name	CAS No. EC No. REACH No. Index No.	Concentration	Classification	H-phrases M factor acute M factor chronic	Note
Doxorubicin hydrochloride	25316-40-9 246-818-3 - -	100%	Acute Tox. 4 - oral, Carc. 1B	H302, H350 - -	-

Molecular weight

579.98

Substance additional information

For the complete text of H- / EUH-statements mentioned in this section, see section 16.

SECTION 4: First aid measures

4.1. Description of first aid measures

Get medical attention if any discomfort continues. Show this Safety Data Sheet (SDS) to medical personnel.

Inhalation

IF INHALED: Remove person to fresh air and keep comfortable for breathing. In case of persistent throat irritation or coughing: Seek medical attention and bring these instructions.

Skin contact

IF ON SKIN: Wash with plenty of water. Continue to rinse for at least 15 minutes and seek medical attention. Get medical advice/attention if you feel unwell.

Eye contact

Remove contact lenses if present. Rinse eyes with water. Continue to rinse for at least 15 minutes and seek medical attention.

Ingestion

IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. Get medical advice/attention if you feel unwell.

Information for doctors

First aiders/ medical personnel need to protect themselves.

4.2. Most important symptoms and effects, both acute and delayed

The severity of the symptoms described will vary dependant of the concentration and the length of exposure.

According to Regulation (EC) No 1907/2006

According to Regulation (EC) No 2020/878

Doxorubicin hydrochloride

Version number: 2
 Issued: 2024-02-01
 Replaces SDS: 2019-03-27



Inhalation

Single exposure may cause the following adverse effects: Upper respiratory irritation. Difficulty in breathing.

Skin contact

Single exposure may cause the following adverse effects: Severe skin irritation.

Eye contact

Single exposure may cause the following adverse effects: Severe irritation.

Ingestion

Single exposure may cause the following adverse effects: Severe abdominal pain. Nausea, vomiting.

4.3. Indication of any immediate medical attention and special treatment needed

Treat symptomatically. No special treatment requirement.

SECTION 5: Firefighting measures

5.1. Extinguishing media

Suitable extinguishing media

In case of fire: Use foam, carbon dioxide, dry powder or water fog to extinguish.

Unsuitable extinguishing media

No specific fire fighting procedure given.

5.2. Special hazards arising from the substance or mixture

Specific hazards: None.

Thermal decomposition or combustion may liberate carbon oxides and other toxic gases or vapours.

Carbon dioxide (CO₂). Carbon monoxide (CO).

Hydrogen Chloride gas

Nitrous gases (NO_x).

5.3. Advice for firefighters

Special protective equipment for fire-fighters

Evacuate area. Avoid breathing gas, fume, vapours or spray. Cool containers exposed to heat with water spray and remove container, if no risk is involved.

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

Avoid breathing dust/fume/gas/mist/vapours/spray. Provide adequate ventilation. Avoid contact with skin and eyes. For personal protection, see section 8.

6.2. Environmental precautions

Avoid discharge into drains, water courses or onto the ground.

According to Regulation (EC) No 1907/2006

According to Regulation (EC) No 2020/878

Doxorubicin hydrochloride

Version number: 2
 Issued: 2024-02-01
 Replaces SDS: 2019-03-27



6.3. Methods and material for containment and cleaning up

Collect spillage with shovel, broom or the like and reuse, if possible. Dispose of large amounts of spillage/waste according to agreement with local authorities.

6.4. Reference to other sections

For personal protection, see section 8. For waste disposal, see section 13.

SECTION 7: Handling and storage

7.1. Precautions for safe handling

Preventive handling precautions

For precautions see section 2.2. Work under hood Wear protective clothing, gloves, eye and face protection. Avoid contact with skin and eyes. Do not breathe dust/fume/gas/mist/vapours/spray. Avoid ingestion and inhalation.

General hygiene

Observe good chemical hygiene practices. Keep away from food, drink and animal feeding stuffs. Do not eat, drink or smoke when using this product. Remove contaminated clothing and launder thoroughly before re-use. Wash skin thoroughly after handling.

7.2. Conditions for safe storage, including any incompatibilities

Store in a dry place. Store in a closed container.

Recommended storage temperature: 2 to 8°C (35.6 to 46.4°F)

Moisture Sensitive. Light sensitive.

7.3. Specific end use(s)

No specific usage precautions noted.

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

No data available

8.2. Exposure controls

Personal Protective Equipment Symbols



Eye / face protection

Wear eye protection.

According to Regulation (EC) No 1907/2006

According to Regulation (EC) No 2020/878

Doxorubicin hydrochloride

Version number: 2
 Issued: 2024-02-01
 Replaces SDS: 2019-03-27



Hand protection

Wear protective gloves. Recommended gloves: Nitrile.

Glove Thickness: 0.11mm

Breakthrough time: 8 hours

Always inspect gloves before use. If signs of wear and tear are noticed then the gloves should be replaced.

No specific hygiene procedures noted, but good personal hygiene practices are always advisable, especially when working with chemicals. Wash contaminated skin thoroughly after handling.

Other skin protection

Wash skin thoroughly after handling.

Respiratory protection

Provide adequate ventilation. If ventilation is insufficient, suitable respiratory protection must be provided.

Environmental exposure controls

Avoid discharge into drains.

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Physical state

Solid

Colour

Orange.

Odour

Odourless.

Melting point / freezing point

216 °C

Boiling point or initial boiling point and boiling range

No data available

Flammability

No data available

Lower and upper explosion limit

No data available

Flash point

No data available

According to Regulation (EC) No 1907/2006

According to Regulation (EC) No 2020/878

Doxorubicin hydrochloride

Version number: 2
 Issued: 2024-02-01
 Replaces SDS: 2019-03-27



Auto-ignition temperature

No data available

Decomposition temperature

No data available

pH

No data available

Kinematic viscosity

No data available

Solubility

No data available

Partition coefficient n-octanol/water

No data available

Vapour pressure

No data available

Density and/or relative density

No data available

Relative vapour density

No data available

Particle characteristics

No data available

9.2. Other information

No data available

SECTION 10: Stability and reactivity

10.1. Reactivity

There are no known reactivity hazards associated with this product.

10.2. Chemical stability

Stable under the prescribed storage conditions.

10.3. Possibility of hazardous reactions

Caution! In contact with nitrites, nitrates, nitrous acid possible liberation of nitrosamines!

Violent reactions possible with:

Strong oxidising agents.

10.4. Conditions to avoid

No data available

According to Regulation (EC) No 1907/2006

According to Regulation (EC) No 2020/878

Doxorubicin hydrochloride

Version number: 2
Issued: 2024-02-01
Replaces SDS: 2019-03-27



10.5. Incompatible materials

Strong oxidising agents.

10.6. Hazardous decomposition products

See section 5.

SECTION 11: Toxicological information

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

Acute toxicity

Product / Substance name CAS / EC no.	Dose descriptor	Value / Dose	Exposure route	Test animals
Doxorubicin hydrochloride 25316-40-9 / 246-818-3	LD50	570 mg/kg	Oral	Mouse

Germ cell mutagenicity

Product / Substance name CAS / EC no.	Result	Exposure route	Metabolic activation / Exposure	Species	Method / Guideline
Doxorubicin hydrochloride 25316-40-9 / 246-818-3	Positive.	-	with and without metabolic activation	Salmonella typhimurium	Ames test
Doxorubicin hydrochloride 25316-40-9 / 246-818-3	Negative.	-	without metabolic activation	Escherichia coli	Ames test
Doxorubicin hydrochloride 25316-40-9 / 246-818-3	Positive.	-	with metabolic activation	Mouse lymphoma test	-
Doxorubicin hydrochloride 25316-40-9 / 246-818-3	Positive.	-	without metabolic activation	Chinese Hamster cells: Ovary	Mutagenicity (mammal cell test): Chromosome aberration:
Doxorubicin hydrochloride 25316-40-9 / 246-818-3	Positive.	Intraperitoneal.	-	Rat bone marrow	Chromosome aberration:
Doxorubicin hydro-	Positive results	Intraperitoneal.	-	Mouse Red blood	Micronucleus test

According to Regulation (EC) No 1907/2006

According to Regulation (EC) No 2020/878

Doxorubicin hydrochloride

Version number: 2
Issued: 2024-02-01
Replaces SDS: 2019-03-27



Product / Sub- stance name CAS / EC no.	Result	Exposure route	Metabolic activa- tion / Exposure	Species	Method / Guideline
chloride 25316-40-9 / 246- 818-3	were obtained in some in vitro tests.			cells (erythrocytes)	
Doxorubicin hydro- chloride 25316-40-9 / 246- 818-3	Positive.	-	-	Mouse	dominant lethal test

Carcinogenicity

Product / Substance name CAS / EC no.	Other
Doxorubicin hydrochloride 25316-40-9 / 246-818-3	Potentially carcinogenic to humans.

Reproductive toxicity

Product / Substance name CAS / EC no.	Result
Doxorubicin hydrochloride 25316-40-9 / 246-818-3	May damage the unborn child.
Doxorubicin hydrochloride 25316-40-9 / 246-818-3	May damage fertility.

Aspiration hazard

Based on available data, the classification criteria are not met.

11.2. Information on other hazards

No data available

SECTION 12: Ecological information

12.1. Toxicity

No data available

12.2. Persistence and degradability

No data available

12.3. Bioaccumulative potential

No data available

According to Regulation (EC) No 1907/2006

According to Regulation (EC) No 2020/878

Doxorubicin hydrochloride

Version number: 2
 Issued: 2024-02-01
 Replaces SDS: 2019-03-27



12.4. Mobility in soil

No data available

12.5. Results of PBT and vPvB assessment

No data available

12.6. Endocrine disrupting properties

This product does not contain any known or suspected endocrine disruptors.

12.7. Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1. Waste treatment methods

Disposal considerations

Dispose of contents/container in accordance with local/regional/national/international regulations.

SECTION 14: Transport information

14.1. UN number

Not applicable

14.2. UN proper shipping name

Not applicable

14.3. Transport hazard class(es)

Not applicable

14.4. Packing group

Not applicable

14.5. Environmental hazards

Not applicable

14.6. Special precautions for user

Not applicable

14.7. Maritime transport in bulk according to IMO instruments

Not applicable

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

EU regulations

This material safety data sheet complies with the requirements of Regulation (EC) No. 1907/2006.

This material safety data sheet complies with the requirements of Regulation (EU) 2020/878.

According to Regulation (EC) No 1907/2006

According to Regulation (EC) No 2020/878

Doxorubicin hydrochloride

Version number: 2
Issued: 2024-02-01
Replaces SDS: 2019-03-27



National regulations

No data available

15.2. Chemical safety assessment

No data available

SECTION 16: Other information

Phrase meaning

Carc. 1B - Carcinogenicity, hazard category 1B

Acute Tox. 4 - oral - Acute toxicity, oral, hazard category 4

H302 Harmful if swallowed.

H350 May cause cancer.